• 1
    Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:203847.
  • 2
    Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL et al. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:215469.
  • 3
    Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 2006;16:7987.
  • 4
    Rangaswami H, Bulbule A, Kundu GC. JNK1 differentially regulates osteopontin-induced nuclear factor-inducing kinase/MEKK1-dependent activating protein-1-mediated promatrix metalloproteinase-9 activation. J Biol Chem 2005;280:1938192.
  • 5
    Rangaswami H, Bulbule A, Kundu GC. Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. J Biol Chem 2004;279:3892135.
  • 6
    O’Regan A, Berman JS. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol 2000;81:37390.
  • 7
    Yokosaki Y, Tanaka K, Higashikawa F, Yamashita K, Eboshida A. Distinct structural requirements for binding of the integrins αvβ6, αvβ3, αvβ5, α5β1 and α9β1 to osteopontin. Matrix Biol 2005;24:41827.
  • 8
    Barry ST, Ludbrook SB, Murrison E, Horgan CM. Analysis of the α4β1 integrin-osteopontin interaction. Exp Cell Res 2000;258:34251.
  • 9
    Ikeda T, Shirasawa T, Esaki Y, Yoshiki S, Hirokawa K. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest 1993;92:281420.
  • 10
    Giachelli CM, Base N, Almeida MM, Denhardt DT, Alpers CE, Schwartz SM. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 1993;92:168696.
  • 11
    Isoda K, Kamezawa Y, Ayaori M, Kusuhara M, Tada N, Ohsuzu F. Osteopontin transgenic mice fed a high-cholesterol diet develop early fatty-streak lesions. Circulation 2003;107:67981.
  • 12
    Kurata M, Okura T, Watanabe S, Fukuoka T, Higaki J. Osteopontin and carotid atherosclerosis in patients with essential hypertension. Clin Sci 2006;111:31924.
  • 13
    Ohmori R, Momiyama Y, Taniguchi H, Takahashi R, Kusuhara M, Nakamura H et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 2003;170:3337.
  • 14
    Kato R, Momiyama Y, Ohmori R, Tanaka N, Taniguchi H, Arakawa K et al. High plasma levels of osteopontin in patients with restenosis after percutaneous coronary intervention. Arterioscler Thromb Vasc Biol 2006;26:e12.
  • 15
    Speer MY, McKee MD, Guldberg RE, Liaw L, Yang HY, Tung E et al. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med 2002;196:104755.
  • 16
    Kielstein JT, Böger RH, Bode-Böger SM, Frölich JC, Haller H, Ritz E et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002;13:1706.
  • 17
    Martens-Lobenhoffer J, Bode-Böger SM. Fast and efficient determination of arginine, symmetric dimethylarginine, and asymmetric dimethylarginine in biological fluids by hydrophilic-interaction liquid chromatography-electrospray tandem mass spectrometry. Clin Chem 2006;52:48893.
  • 18
    Kuehnle HF, Von DK, Schmidt FH. Fully enzymatic inulin determination in small volume samples without deproteinization. Nephron 1992;62:1047.
  • 19
    Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function – a meta-analysis. Nephrol Dial Transplant 2006;21:244651.
  • 20
    Kielstein JT, Salpeter SR, Buckley NS, Cooke JP, Fliser D. Two cardiovascular risk factors in one? Homocysteine and its relation to glomerular filtration rate. A meta-analysis of 41 studies with 27,000 participants Kidney Blood Press Res 2008;31:25967.
  • 21
    Kleinman JG, Beshensky A, Worcester EM, Brown D. Expression of osteopontin, a urinary inhibitor of stone mineral crystal growth, in rat kidney. Kidney Int 1995;47:158596.
  • 22
    Ophascharoensuk V, Giachelli CM, Gordon K, Hughes J, Pichler R, Brown P et al. Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int 1999;56:57180.
  • 23
    Persy VP, Verstrepen WA, Ysebaert DK, De Greef KE, De Broe ME. Differences in osteopontin up-regulation between proximal and distal tubules after renal ischemia/reperfusion. Kidney Int 1999;56:60111.
  • 24
    Wolak T, Kim H, Ren Y, Kim J, Vaziri ND, Nicholas SB. Osteopontin modulates angiotensin II-induced inflammation, oxidative stress, and fibrosis of the kidney. Kidney Int 2009;76:3243.
  • 25
    Jackle I, Gunther W, Von Gise H, Alt JM, Bohle A, Stolte H. Kidney function and protein excretion in relation to pathomorphology of glomerular diseases. Contrib Nephrol 1988;68:12835.
  • 26
    Nikolic-Paterson DJ, Atkins RC. The role of macrophages in glomerulonephritis. Nephrol Dial Transplant 2001;16(Suppl. 5):37.
  • 27
    Minoretti P, Falcone C, Calcagnino M, Emanuele E, Buzzi MP, Coen E et al. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J 2006;27:8027.
  • 28
    Brosius FC III, Hostetter TH, Kelepouris E, Mitsnefes MM, Moe SM, Moore MA et al. American Heart Association Kidney and Cardiovascular Disease Council; Council on High Blood Pressure Research; Council on Cardiovascular Disease in the Young; Council on Epidemiology and Prevention; Quality of Care and Outcomes Research Interdisciplinary Working Group: Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. Circulation 2006;114:10837.
  • 29
    Kilic T, Oner G, Ural E, Yumuk Z, Sahin T, Bildirici U et al. Comparison of the long-term prognostic value of Cystatin C to other indicators of renal function, markers of inflammation and systolic dysfunction among patients with acute coronary syndrome. Atherosclerosis 2009;207:5528.
  • 30
    Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int Suppl 2003;S10510.
  • 31
    Böger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009;119:1592600.
  • 32
    Böger RH, Maas R, Schulze F, Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality – an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res. 2009;60:4817.
  • 33
    Giachelli C, Bae N, Lombardi D, Majesky M, Schwartz S. Molecular cloning and characterization of 2B7, a rat mRNA which distinguishes smooth muscle cell phenotypes in vitro and is identical to osteopontin (secreted phosphoprotein I, 2aR). Biochem Biophys Res Commun 1991;177:86773.
  • 34
    Gadeau AP, Campan M, Millet D, Candresse T, Desgranges C. Osteopontin overexpression is associated with arterial smooth muscle cell proliferation in vitro. Arterioscler Thromb 1993;13:1205.
  • 35
    Ihara H, Denhardt DT, Furuya K, Yamashita T, Muguruma Y, Tsuji K et al. Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin. J Biol Chem 2001;276:1306571.
  • 36
    Steitz SA, Speer MY, McKee MD, Liaw L, Almeida M, Yang H et al. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol 2002;161:203546.
  • 37
    Wada T, McKee MD, Steitz S, Giachelli CM. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res 1999;84:16678.
  • 38
    Miyauchi A, Alvarez J, Greenfield EM, Teti A, Grano M, Colucci S et al. Recognition of osteopontin and related peptides by an αvβ3 integrin stimulates immediate cell signals in osteoclasts. J Biol Chem 1991;266:2036974.